Author:
Bayik Defne,Lauko Adam J.,Roversi Gustavo A.,Serbinowski Emily,Acevedo-Moreno Lou-Anne,Lanigan Christopher,Orujov Mushfig,Lo Alice,Alban Tyler J.,Kim Adam,Silver Daniel J.,Nagy Laura E.,Brown J. Mark,Allende Daniela S.,Aucejo Federico N.,Lathia Justin D.
Abstract
Abstract
Myeloid-derived suppressor cells (MDSCs) are immunosuppressive cells that are increased in patients with numerous malignancies including viral-derived hepatocellular carcinoma (HCC). Here, we report an elevation of MDSCs in the peripheral blood of patients with other hepatobiliary malignancies including non-viral HCC, neuroendocrine tumors (NET), and colorectal carcinoma with liver metastases (CRLM), but not cholangiocarcinoma (CCA). The investigation of myeloid cell infiltration in HCC, NET and intrahepatic CCA tumors further established that the frequency of antigen-presenting cells was limited compared to benign lesions, suggesting that primary and metastatic hepatobiliary cancers have distinct peripheral and tumoral myeloid signatures. Bioinformatics analysis of The Cancer Genome Atlas dataset demonstrated that a high MDSC score in HCC patients is associated with poor disease outcome. Given our observation that MDSCs are increased in non-CCA malignant liver cancers, these cells may represent suitable targets for effective immunotherapy approaches.
Funder
National Institutes of Health
Case Comprehensive Cancer Center, Case Western Reserve University
Cleveland Clinic Foundation Liver Cancer Center of Excellence
Publisher
Springer Science and Business Media LLC
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献